Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.65 |
| ▸ | DRD4 | P21917 | 10/20 | 0.65 |
| ▸ | DRD3 | P35462 | 10/20 | 0.65 |
| ▸ | DRD1 | P21728 | 2/20 | 0.65 |
| ▸ | DRD5 | P21918 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028601 | 0.86 | DRD2 (0.63) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL22614226 | 0.86 | DRD2 (0.69) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL8864160 | 0.85 | DRD2 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL8864198 | 0.85 | DRD2 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL5640879 | 0.85 | DRD2 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL8864139 | 0.85 | DRD2 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL8864132 | 0.85 | DRD2 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL8864656 | 0.85 | DRD2 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| Bromide SCHEMBL6281511 | 0.84 | DRD2 (0.70) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10367377 | 0.82 | HTR1A (0.49) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699860-B2 | ADRENERGIC BLOCKING AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | claimed |
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
| US-6919371-B2 | 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1389202-B1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040072828-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-6699860-B2 | ADRENERGIC BLOCKING AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6660752-B2 | Adrenergic blocking agents | BAYER PHARMACEUTICALS CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | DRD2 162/4885DRD4 366/4885DRD3 70/4885 |
| US-20040072828-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | DRD2 162/4885DRD4 366/4885DRD3 70/4885 |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | DRD2 162/4885DRD4 366/4885DRD3 70/4885 |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | DRD2 108/4885DRD4 184/4885DRD3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.